Home > Boards > US OTC > Medical - Drugs >

Sirona Bio-Chem Corp (SRBCF)

SRBCF RSS Feed
Add SRBCF Price Alert      Hide Sticky   Hide Intro
Moderator: Serael
Search This Board: 
Last Post: 12/4/2019 2:12:40 PM - Followers: 10 - Board type: Free - Posts Today: 0

 

Sirona Bio-Chem: is a 2011 TSX VENTURE 50 COMPANY     TSX-V.  SVM  

SRBCF trades on the OTCQX

 -   

Welcome to the new SIROMA BIO-CHEM  stock board. 

http://www.sironabiochem.com/

OVERVIEW

Launched in 2009, Sirona Biochem is developing programs in three major streams:

*Therapeutics - Diabetes and Cancer
*Cosmeceuticals - Anti-aging Depigmenting Agents (skin lighteners)
*Biological Ingredients - Inducers and Adjuvants for biological developments

 

Our expertise lies within our proprietary chemistry technology.  We have developed a chemistry technique to improve the pharmaceutical qualities of carbohydrate-based molecules.

Carbohydrates, or sugar molecules, perform numerous roles in living organisms and are essential to life.  Their importance to life makes them valuable for the development of therapeutics and cosmeceuticals.

While carbohydrate-based molecules have broad application potential, they are challenging to develop.  Due to the complexity of carbohydrates, these molecules can easily break down and become toxic when exposed.

Sirona Biochem has developed a fluorination technique to maintain the integrity of carbohydrate-based molecules even after exposure to enzymes known to typically negatively affect them.  This proprietary technique has allowed Sirona Biochem to explore the immense opportunities carbohydrate-based molecules can offer.

Sirona Biochem’s development focus is centred around three high-valued programs, selected based on our research expertise in the area, market potential, development timelines and high return on investment.

Carbohydrate-based molecules have several applications such as:

We believe this chemistry method can be applied to drugs in development to improve their properties, discontinued drugs that may have been shelved for stability reasons, or for the development of new products for cosmetics and biological manufacturing.  Using our proprietary chemistry process, we feel we can maximize the commercial value of carbohydrate-based molecules.

Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients.  Our two most advanced programs include a diabetes treatment candidate and a cosmetic skin lightening agent. 

Our sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and is being considered for market approval in Europe.  We have begun partnering discussions to review options for the outlicensing of our SGLT inhibitor.  A pharmaceutical partner would handle the downstream clinical and commercial needs of our program.

Recognized for the scientific innovation at our laboratory in France, the French government awarded our team an innovation grant worth CDN$1.9 Million to develop our cosmetic skin lightener program to a commercial ready stage.  Several efficacy and stability studies have been completed with results showing superiority over popular commercial products.  Further toxicity studies are underway.

Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.  In addition to the diabetesskin lightener,anti-aging and biological ingredients programs, the company is exploring development of the following:

Cancer Vaccine Antigen

Our scientists have formulated a Tn antigen that could be valuable as a key component for the development of a cancer vaccine.

In healthy individuals, certain antigens are suppressed by the body’s immune system. In patients with cancer, research has shown that a higher presence of Tn antigens on the cell surface are linked to higher malignancy and growth. These antigens promote cancer cell adhesion and thus are linked to cancer metastases, allowing cancer to spread from one organ to another.  By producing a synthetic version of the Tn antigen it can be used in a vaccine that can potentially trigger the immune system to recognize it as a foreign substance. Previous attempts by scientists to develop a vaccine with the Tn antigen have been unsuccessful due to the chemistry challenges in stabilizing the molecule.


Pipeline
https://www.sironabiochem.com/wp-content/uploads/2018/04/Pipeline-Apr2018.png
Therapeutics

Sirona Biochem's technology platform of enhancing carbohydrate-based molecules has potential for the development of several blockbuster therapeutics for the treatment of diabetes, obesity, cancer, cardiovascular disease, pain and inflammation. Currently, our therapeutic focus is on the development of a Sodium Glucose Transporter (SGLT) inhibitor for Type 2 diabetes and a cancer vaccine antigen.

Sodium Glucose Transporter (SGLT) Inhibitors - Diabetes & Obesity

Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.

The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.

Competive Advantage

Sirona Biochem's goal is to develop a best-in-class SGLT inhibitor for Type 2 diabetes. By applying our proprietary chemistry technique, we believe we can produce a drug candidate with optimal pharmaceutical characteristics including, but not limited to, enhanced stability, bioavailability, selectivity and/or efficacy.

There are no SGLT inhibitors available on the market. The most advanced SGLT inhibitor, dapagliflozin, developed by Bristol Myers Squibb and AstraZeneca, is being reviewed for market approval by the Food & Drug Administration with a decision expected in the first quarter of 2012. In a comparative preclinical study, Sirona Biochem's SGLT inhibitor drug candidate appeared to outperform dapagliflozin. Sirona Biochem aims to develop an improved product.

Status & Milestones

Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.

Markets

According to the World Health Organization, more than 220 million people worldwide suffer from diabetes. Approximately 90% of diabetes patients suffer from Type 2 diabetes. The WHO estimates that diabetes-related deaths will double from 2005 to 2030. In 2009, an estimated $25 billion was spent globally on diabetes treatment. Diabetes is the fourth largest pharmaceutical market.

In Canada, diabetes is the 6th leading cause of death. The Canadian Diabetes Association estimates that by 2020, one in ten Canadian will have diabetes. It's estimated that diabetes costs the Canadian healthcare system more than $12 billion a year.

With sedentary lifestyles becoming so common, the prevalence of diabetes is increasing rapidly. While there are several medications on the market, there remains a major unmet medical need for new improved diabetes medications. Sales of Januvia, a diabetes medication launched in 2006, reached US$1.6 billion in annual sales by 2009. By 2013, it's estimated sales of Januvia will reach US$4.5 billion.

Cancer Antigen

Our scientists have formulated a Tn antigen that could be valuable as a key component for the development of a cancer vaccine.

In healthy individuals, certain antigens are suppressed by the body's immune system. In patients with cancer, research has shown that a higher presence of Tn antigens on the cell surface are linked to higher malignancy and growth. These antigens promote cancer cell adhesion and thus are linked to cancer metastases, allowing cancer to spread from one organ to another. By producing a synthetic version of the Tn antigen it can be used in a vaccine that can potentially trigger the immune system to recognize it as a foreign substance. Previous attempts by scientists to develop a vaccine with the Tn antigen have been unsuccessful due to the chemistry challenges in stabilizing the molecule.




Management

 

Howard J. Verrico, MD
Ceo and Chairman of the Board
V-card

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.

 

Géraldine Deliencourt-Godefroy, PhD

Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.

Christopher Hopton, CGA
Chief Financial Officer
V-card

Mr. Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 15 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.

 
 https://www.sironabiochem.com/wp-content/uploads/2011/06/Seltenrich-head-shot-small.jpg    Michelle Seltenrich, MBA
     Vice President, Operations

     Michelle Seltenrich brings 17 years of expertise in public biotech companies. Her experience ranges from both academic and industry R&D lab management to corporate mergers and
     acquisitions. Ms. Seltenrich was previously the Manager of Business Development at Forbes MediTech and was responsible for international business development, in-licensing and M&A.
     She played a key role in the successful acquisition of a U.S. based biotech company.
     Ms. Seltenrich holds a BSc from the University of British Columbia and an MBA in Technology Management from Simon Fraser University




Board of Directors

Howard J. Verrico, MD, Chairman of the Board, Founder and Secretary – Director
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.





Géraldine Deliencourt-Godefroy, PhD, Chief Scientific Officer & Director
Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of France-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.



Christopher Hopton, Director
Mr. Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 15 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.



Alex Sandro Marazzi, MD, Director
Dr. Marazzi is a family physician with certification in both Family and Emergency Medicine. He has been in family practice in Mission, British Columbia since 1997. He is also a part owner of a well established walk-in-clinic. Most recently he served as the Chief of the Emergency Department at Mission Memorial Hospital. Prior to practicing medicine in British Columbia, Dr. Marazzi was an Emergency Room physician for 7 years in Midland, Ontario. Dr. Marazzi earned his Bachelor of Pharmaceutical Sciences at UBC in 1985. While studying medicine he worked as a Hospital Pharmacist at Langley Memorial Hospital. He earned his Doctor of Medicine at UBC in 1989 and pursued an internship at Toronto East General Hospital.


 

    Jason Tian , Director
   Jason Tian has been providing legal services to international clients since 2007 and has worked in top firms in China such as Beijing 
    Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a Senior Partner of Shanghai Landing Law Offices. He also worked as senior legal translator in UK-based firm, Clifford
    Chance LLP, before starting his legal career.

    Shanghai Landing Law Offices is a full-service law firm with headquarters in Shanghai, China. Lawyers at Landing provide full-service to clients in industries such as healthcare and
    pharmaceuticals as well as consumer retail in China. Landing has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia,
    Bangladesh, Philippines and Cambodia.





Scientific Advisory Board
 

DR. DENIS RICHARDPH.D.

Dr. Denis Richard earned his Ph.D. in Physiology at Laval University and received further postdoctoral training in nutrition and physiology at the Dunn Nutrition Unit at the University of Cambridge, Cambridge, England.
Dr. Richard is a full professor at the Department of Medicine at Université Laval. Together with serving as director of the Research Centre of the Institut de Cardiologie et de Pneumologie de Québec, and director of the Groupe Interdisciplinaire de Recherche sur l’Obésité de l’Université Laval, he is the recipient of the Merck Frosst / CIHR Research Chair in Obesity, the first Chair devoted to obesity research in Canada. He is active with several societies and associations and is a member of: The Canadian Obesity Network, The American Physiological Society, The Society for Neuroscience, The Endocrine Society, and The Society for the Study of Ingestive Behavior.
Dr. Richard is a well-established scientist with regard to the study of (i) neurosystems involved in the control and regulation of food intake, thermogenesis, and energy balance, (ii) the mechanisms whereby the gastrointestinal hormones influence energy balance regulation, (iii) the relationship between stress and obesity, (iv) the role of the sympathetic nervous system in controlling uncoupling protein 1 in brown adipose tissue, and (v) the role of uncoupling protein 2 in energy metabolism, oxidative stress and neuroprotection. He lists over 200 publications in his career.

DR. BRUCE VERCHERE, PH.D.

Dr. Bruce Verchere is a Professor in the Departments of Surgery and Pathology & Laboratory Medicine at the University of British Columbia (UBC).  He is also head of the Diabetes Research Program at the Child & Family Research Institute, and holds the Irving K Barber Chair in Diabetes Research.  Dr. Verchere’s research aims to understand the function of pancreatic islet beta cells and their relevance in both type 1 and type 2 diabetes, with a goal of developing therapeutic approaches for enhancing beta cell survival and function. He has published more than 90 manuscripts in the field of islet biology and diabetes and has been invited to present his research worldwide. Dr. Verchere was a Senior Scholar of the Michael Smith Foundation for Health Research (MSFHR) and was awarded the UBC Outstanding Young Alumnus award in 2000 and the Canadian Diabetes Association Young Scientist award in 2006. He is currently chair of the CIHR Diabetes Obesity Lipid and Lipoprotein Disorders panel, Chair of the National Research Council of the Canadian Diabetes Association, and Chair of the MSFHR Research Advisory Council. He currently sits on the editorial board of the publications Diabetes and Canadian Journal of Diabetes.
 

DR. MICHAEL WALKERPH.D.

Dr. Michael Walker has been a director and CEO of Verona Pharma since September 2006. He is an Emeritus Professor at the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Canada and has founded and managed various biotech companies in Canada and the UK. His research interests are wide including many aspects of general pharmacology (from basic to clinical studies), marine toxins and respiratory and cardiac pharmacology.
Dr. Walker was the founder of Rhythm Search Developments (RSD) Ltd., which company evolved into Nortran Pharmaceuticals Inc. and subsequently Cardiome Pharma Corp. (TSX:COM, NASDAQ: CRME) whose drug, RSD1235, for the acute termination of atrial fibrillation (a disorder of heart beating), is currently the subject of a New Drug Application filed with the US Food and Drug Administration.

 



Recent News

 
SRBCF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1317  Sticky Note Sirona Biochem Signs Definitive License & Supply Agreement Serael 09/18/19 02:50:44 PM
#1323   I heard some rumors about news before Chrismas Serael 12/04/19 02:12:39 PM
#1322   Waiting for news Serael 11/29/19 03:14:45 PM
#1321   News out ! Serael 10/09/19 07:37:39 AM
#1320   Sirona Biochem: Multiple Catalysts Ahead After Breakthrough Serael 10/04/19 11:44:37 AM
#1319   Sirona Biochem: Breakthrough article ! Serael 09/21/19 03:30:16 AM
#1318   impressive developments of Sirona Biochem in the last nev_investor 09/19/19 01:09:27 PM
#1317   Sirona Biochem Signs Definitive License & Supply Agreement Serael 09/18/19 02:50:44 PM
#1316   Sirona Biochem Adopts Shareholder Rights Plan Serael 09/13/19 09:41:24 AM
#1315   The definitive agreement is expected to be signed Serael 09/13/19 09:36:20 AM
#1314   Sirona is pleased to announce that a non-binding Serael 09/13/19 09:33:37 AM
#1313   target CAD 0.98, new Report : http://de.slideshare.net/MomentumPR/first-berlin-e xr_biotech_consult 03/10/16 04:00:48 PM
#1312   new presentation out: page 29!! xr_biotech_consult 01/22/16 02:37:51 PM
#1311   Sirona Biochem Discovers Unexpected Ancillary Effects of Its starbuxsux 05/26/15 01:36:22 PM
#1310   Sirona Biochem to Present at BioNetwork East -- starbuxsux 04/14/15 09:26:26 AM
#1309   Sirona Biochem Announces Successful Development of a Third starbuxsux 03/11/15 12:02:08 PM
#1308   Sirona Biochem Invited to Present at Dose of starbuxsux 01/26/15 01:42:46 PM
#1307   Sirona Biochem's Subsidiary TFChem Awarded Prestigious French Innovation Tro starbuxsux 12/02/14 03:47:01 PM
#1306   Sirona Biochem Names Attila Hajdu as Chief Business starbuxsux 10/27/14 12:11:53 PM
#1305   Sirona Biochem Launches Anti-Aging Preclinical Studies starbuxsux 09/22/14 10:20:21 AM
#1304   Sirona Biochem Announces Positive Results of PK Study starbuxsux 09/04/14 02:31:55 AM
#1303   Sirona Biochem Launches Global Awareness Campaign With Cousteau starbuxsux 08/21/14 09:54:31 AM
#1302   Sirona Subsidiary, TFChem, Receives CDN$1.2 Million for Anti-Aging Project[/b starbuxsux 08/19/14 03:30:34 PM
#1301   a real interesting read!!! Diva1963 08/05/14 10:03:51 AM
#1300   Sirona Biochem Announces Successful Synthesis of Anti-Inflammatory Compound starbuxsux 07/31/14 01:27:43 PM
#1299   Sirona Biochem Announces Successful Completion of Two First starbuxsux 07/23/14 08:12:55 AM
#1298   Sirona Announces Shares for Services Agreement starbuxsux 07/22/14 05:03:27 PM
#1297   Sirona Biochem Corporation - CEO Letter to Shareholders starbuxsux 07/21/14 10:56:10 AM
#1296   Sirona Biochem CEO Neil Belenkie resigns starbuxsux 06/25/14 08:23:52 AM
#1295   Sirona Biochem's Subsidiary, TFChem, Selected for UBISTART Tour starbuxsux 06/11/14 10:54:35 AM
#1294   Sirona Biochem Announces Wanbang Biopharmaceutical's Launch of Pre-Clinical starbuxsux 06/03/14 08:07:22 AM
#1293   Sirona Biochem Expands Exclusive Skin Lightening License With starbuxsux 05/29/14 08:05:02 AM
#1292   hold 2oo k Shares in Canada, http://web.tmxmoney.com/quote.php?qm_symbol=SBM xr_biotech_consult 05/28/14 02:27:37 PM
#1291   Sirona's Science Boosts Anti-Aging Technology starbuxsux 05/27/14 06:52:01 AM
#1290   Sirona Biochem's Anti-Aging Glycoprotein Successfully Extends Cell Life starbuxsux 05/20/14 08:48:52 AM
#1289   Sirona Grant Stock Options starbuxsux 04/26/14 04:12:57 PM
#1288   Sirona Biochem Announces Collaboration With Magellan BioScience starbuxsux 04/23/14 10:50:38 AM
#1287   Sirona Engages Torrey Hills Capital starbuxsux 04/17/14 10:17:11 AM
#1286   Sirona Biochem Announces Open Webinar for Q&A starbuxsux 04/03/14 09:14:00 AM
#1285   Sirona Biochem Announces Patent for Anti-Aging Family of starbuxsux 04/01/14 01:53:58 PM
#1284   Nice!! ZLAZARUS 03/27/14 04:04:37 PM
#1283   Sirona Biochem Announces Jacques Cousteau's Son and Grandson starbuxsux 03/27/14 04:00:25 PM
#1282   Sirona Biochem Welcomes Claude Nivet, New Laboratory Operations starbuxsux 03/23/14 12:52:31 PM
#1281   Nice! ZLAZARUS 03/10/14 10:58:39 AM
#1280   Sirona Biochem Closes Private Placement starbuxsux 03/10/14 10:56:20 AM
#1279   Thanks ZLAZARUS 02/01/14 01:53:12 AM
#1278   I think its around 230M including all the _db_ 01/29/14 03:15:13 PM
#1277   Bux it's just a matter of time. ZLAZARUS 01/29/14 09:24:08 AM
#1276   Sirona Biochem Completes Global Exclusive Licensing Agreement with starbuxsux 01/29/14 09:20:51 AM
#1275   Sirona Biochem Completes Exclusive Licensing Agreement With Leading starbuxsux 01/27/14 08:23:18 AM
#1274   right on! buccaneer1961 01/27/14 02:10:22 AM
PostSubject